Day Traders Tag icon

×
On Friday, Johnson & Johnson (NYSE:JNJ) announced discontinuing the Phase 2 field study evaluating the efficacy of investigational antiviral candidate mosnodenvir to prevent dengue virus in adults aged 18-65. The decision to discontinue this study is part of a strategic reprioritization of the company’s Communicable Diseases research and development (R&D) portfolio. No safety issues were identified. Efficacy data from the Phase 2 field study will be available once the final data analyses, which are now underway, are complete. Also Read: Johnson & Johnson’s Erleada Shows Improved Overall Survival In ...


In The news